On April 21, 2022 ViewRay, Inc. (Nasdaq: VRAY) reported details relating to the release of its first quarter 2022 financial results (Press release, ViewRay, APR 21, 2022, View Source [SID1234612884]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ViewRay will hold a conference call to discuss results on Thursday, May 5, 2022 at 4:30 p.m. ET. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The confirmation number is 6274157. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at View Source

After the live webcast, a replay will remain available online on the investor relations page of ViewRay’s website, under "Financial Events and Webinars", for 14 days following the call. In addition, a telephonic replay of the call will be available until May 12, 2022. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 6274157.

On April 21, 2022 Terran Biosciences, Inc. ("Terran"), a biotechnology platform company dedicated to the development of transformational therapies for neurological and psychiatric diseases, reported that has entered into an agreement with Sanofi SA ( " Sanofi") for exclusive worldwide rights to develop and commercialize two late-stage SNC portfolio assets (Press release, Sanofi, APR 21, 2022, View Source;_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc [SID1234612883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These therapies generated four investigational new drug (IND) applications and more than 104 clinical studies involving more than 15,000 subjects in various CNS indications.

Terran plans to rapidly advance the development of these actives for neurological and psychiatric indications, including several novel applications where there is a high unmet medical need. This transaction represents the next key stage in the development of these promising assets.

The deal included an upfront payment, as well as typical milestones and royalties based on success. Specific financial terms of the deal were not disclosed.

"We are grateful to the team at Sanofi for entrusting us with the continued development of these late-stage therapies, which we believe have the potential to transform the paradigm of neuropsychiatry," said Dr. Sam Clark , Founder and CEO of Terran.

On April 21, 2022 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, reported that Dr. Milton Werner, Ph.D., the Company’s President & Chief Executive Officer will participate in a fireside chat at the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022 at 2:30pm ET (Press release, Inhibikase Therapeutics, APR 21, 2022, View Source;ophthalmology-conference-301530237.html [SID1234612882])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company’s website, www.inhibikase.com. An archived replay of the webcast will be available for approximately 30 days. In addition, the Company recently hosted a virtual Key Opinion Leader investor event on April 20, 2022. A replay of the event can be accessed here.

On April 21, 2022 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, reported that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the U.S. financial markets close (Press release, Dynavax Technologies, APR 21, 2022, https://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may-5-2022-301526392.html [SID1234612881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dynavax will host a conference call and live audio webcast on Thursday, May 5, 2022 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company’s website at View Source Alternatively, participants may dial (866) 420-4066 or (409) 217-8237 and refer to conference ID 4282730. A replay of the webcast will be available for 30 days following the live event.

On April 21, 2022 Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, reported that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update (Press release, Eiger Biopharmaceuticals, APR 21, 2022, https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-first-quarter-2022-financial-results-and-business-update-on-thursday-may-5-301530543.html [SID1234612880]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and replayed webcast of the call will be available through the company’s website at www.eigerbio.com. To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 2392544. The webcast will be archived and available for replay for at least 90 days after the event.